Home page > Press release

Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025

Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025 The Group has increased its B-Impact score by 16.3...

1/10

Společnost Chiesi sleduje opatření přijatá k zajištění zdravější a udržitelnější budoucnosti

2/10

Chiesi accelerates path toward full sustainability despite Covid-19 pandemic

3/10

ARCHIVE PRESS RELEASE

Chiesi Group calls for #ActionOverWords in the fight against climate change

10 Maio 2021 PRESS

New organisational order for the Chiesi Foundation

03 Maio 2021 PRESS

Chiesi Group receives European Marketing Authorisation for Trimbow® inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) delivered through NEXThaler, an extrafine formulation fixed triple combination therapy fo

21 Abril 2021 PRESS

Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences

06 Abril 2021 PRESS

Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma

01 Fevereiro 2021 PRESS

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).

16 Setembro 2020 PRESS

Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group

02 Julho 2020 PRESS

Smrčkova 2485/4, 180 00 Praha 8,
Česká republika
Phone +420 261 221 745
chiesi-cz@chiesi.com

CHIESI ON THE WEB